-Member Login

Forgot your USERNAME OR PASSWORD?

Job Postings

Let's Stay Connected

Find us on the popular social networks

Facebook Twitter LinkedIn Flicker

Journal Highlights

MOL Highlight: SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis

Posted on 5/5/2017 1:27:58 PM

MOL May Highlight Li et al

Betulinic acid (BA), a natural pentacyclic triterpenoid, can promote anti-inflammation by inhibiting cytokine interleukin 17 and interferon-γ production. This study investigates a BA derivative, SH479, that has a greater inhibitory effect than BA on T helper 17 cell (TH17) differentiation. Although SH479 exhibited an inhibitory effect on CD4+ T helper cells, it had a stimulatory effect on regulatory T cells (Treg). To evaluate the potential of SH479 in treating an autoimmune disease such as multiple sclerosis (MS), the authors show that SH479 ameliorated clinical and histologic signs of experimental autoimmune encephalomyelitis in a mouse model. At the molecular level, SH479 was shown to perturb STAT3, STAT5 and NF-κB signaling pathways to control TH17/Treg balance. The overall data thus suggests that SH479 is a potential novel drug candidate for treating autoimmune diseases such as MS.

See the article by Li et al. at Molecular Pharmacology May 2017, 91 (5) 464-474; DOI: https://doi.org/10.1124/mol.116.107136 

Comments (0)


Leave a comment


Blog comments are moderated and will be posted once approved.

Name


Comment:


Enter the code shown below:

Recent Posts

Archive

.

Hot Links 

Advertise in Explore Pharmacology 2017 

2017 Award Nominations Side 

Join ASPET 

What is Pharmacology? Video 

PharmTalk Blog